Impact of Antibiotics, Steroids, and PPIs on Survival in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

Impact of Antibiotics, Steroids, and PPIs on Survival in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

This nationwide cohort study reveals that certain antibiotics, higher-dose steroids, and proton pump inhibitors are associated with reduced overall survival in advanced NSCLC patients receiving first-line pembrolizumab, underscoring the importance of careful comedication monitoring during immunotherapy.
Ammoxetine Shows Promise as Effective and Well-Tolerated Treatment for Major Depressive Disorder: Insights from a Phase 2 Randomized Trial

Ammoxetine Shows Promise as Effective and Well-Tolerated Treatment for Major Depressive Disorder: Insights from a Phase 2 Randomized Trial

A phase 2 trial in adults with major depressive disorder demonstrated that ammoxetine at 40 mg/d and 60 mg/d significantly improved depressive symptoms compared to placebo and was generally well tolerated, offering a novel treatment option with potentially fewer adverse effects.